Liquidia (NASDAQ:LQDA) CAO Sells $167,804.16 in Stock

Posted by Brenda Bartman on Oct 16th, 2026

Liquidia Corporation (NASDAQ:LQDA – Get Free Report) CAO Dana Boyle sold 5,892 shares of the company’s stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $28.48, for a total transaction of $167,804.16. Following the completion of the sale, the chief accounting officer owned 165,609 shares in the company, valued at $4,716,544.32. This represents a 3.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dana Boyle also recently made the following trade(s):

On Monday, July 27th, Dana Boyle sold 1,600 shares of Liquidia stock. The shares were sold at an average price of $87.53, for a total transaction of $140,048.00.

Liquidia Stock Performance

Shares of LQDA opened at $34.78 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31. The stock has a 50 day moving average price of $61.21 and a two-hundred day moving average price of $61.73. The firm has a market capitalization of $3.11 billion, a P/E ratio of 24.77 and a beta of 0.61. Liquidia Corporation has a 52 week low of $21.94 and a 52 week high of $93.61.

Liquidia (NASDAQ:LQDA – Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The company had revenue of $171.68 million during the quarter, compared to analysts’ expectations of $168.48 million. During the same period last year, the company earned ($0.49) earnings per share. The business’s revenue for the quarter was up 1842.1% compared to the same quarter last year. Equities analysts forecast that Liquidia Corporation will post 2.05 earnings per share for the current fiscal year.

Institutional Trading of Liquidia

Several hedge funds and other institutional investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company grew its stake in Liquidia by 63.3% in the 1st quarter. The Manufacturers Life Insurance Company now owns 58,265 shares of the company’s stock valued at $2,199,000 after buying an additional 22,592 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in Liquidia during the 2nd quarter valued at $29,694,000. Seven Fleet Capital Management LP raised its holdings in Liquidia by 25.2% during the 2nd quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock valued at $20,459,000 after acquiring an additional 51,727 shares during the period. Bank of America Corp DE lifted its position in shares of Liquidia by 18.7% during the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after acquiring an additional 360,372 shares in the last quarter. Finally, Handelsbanken Fonder AB purchased a new stake in shares of Liquidia during the second quarter worth $1,993,000. Institutional investors own 64.54% of the company’s stock.

Key Headlines Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

Positive Sentiment: Liquidia settled all six patent and antitrust disputes with United Therapeutics for a net $380.7 million, allowing continued commercialization of YUTREPIA for pulmonary arterial hypertension. Ending the litigation removes significant legal uncertainty and avoids a potentially market-disrupting appeal. Liquidia shares surge as settlement ends United Therapeutics litigation
Positive Sentiment: Analyst sentiment improved after the settlement. LifeSci Capital upgraded LQDA to “outperform” with a $59 price target, while HC Wainwright raised its target to $65 and initiated or reiterated a “buy” rating. BTIG also upgraded the stock to “buy” with a $70 target. LifeSci Capital upgrades Liquidia
Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were reported at $222.7 million. Management expects existing cash and ongoing sales to fund the settlement and planned clinical programs without requiring additional financing, supporting the investment case if commercial momentum continues.
Positive Sentiment: Trading activity reflected renewed speculative interest, with call-option volume more than doubling its typical level. This suggests some traders are positioning for additional gains following the legal resolution.
Neutral Sentiment: Multiple executives and insiders, including the CEO and CFO, sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax obligations on vested equity awards. Because the transactions were planned and sellers retained substantial holdings, they are a limited standalone signal of sentiment. Liquidia insider sale filing
Negative Sentiment: The $380.7 million settlement will require $175 million within 30 business days, $145.4 million in 2027 installments and $60.3 million tied to antitrust litigation. These payments could materially reduce Liquidia’s cash cushion and constrain future investment.
Negative Sentiment: Liquidia agreed not to appeal the infringement ruling and will remove the PH-ILD indication from YUTREPIA’s label, narrowing the drug’s addressable market. Needham lowered its price target to $58, despite maintaining a “buy” rating, highlighting ongoing execution and valuation risks.

Analyst Upgrades and Downgrades

LQDA has been the topic of a number of recent analyst reports. Zacks Research lowered Liquidia from a “hold” rating to a “strong sell” rating in a report on Tuesday, September 22nd. Royal Bank Of Canada set a $65.00 target price on Liquidia in a research note on Thursday. Wedbush set a $58.00 price target on shares of Liquidia in a report on Friday, October 2nd. Raymond James Financial restated an “outperform” rating on shares of Liquidia in a research report on Thursday, October 8th. Finally, Citigroup restated a “neutral” rating on shares of Liquidia in a research report on Thursday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Liquidia currently has a consensus rating of “Hold” and a consensus target price of $72.85.

Read Our Latest Research Report on LQDA

About Liquidia

(Get Free Report)

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).